Ruxolitinib Treatment During Myelofibrosis Leads to Cutaneous Mycobacterium marinum Infection: A Case Report
Xiaonan Chen,1 Dong Zhang,2 Teng Wang,3 Weiyuan Ma2 1Department of Hematology, Affiliated Hospital of Weifang Medical University, Weifang, People's Republic of China; 2Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, People's Republic of China; 3Depart...
Saved in:
Main Authors: | Chen X (Author), Zhang D (Author), Wang T (Author), Ma W (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
by: Manduzio P
Published: (2017) -
Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012) -
Analyses of clinical and histopathological characteristics of twelve cases of cutaneous Mycobacterium marinum infections
by: Lu YANG, et al.
Published: (2024) -
Cutaneous Mycobacterium marinum infection secondary to well water exposure masquerading as cutaneous Crohn's disease
by: Camilla A. Cascardo, BS, et al.
Published: (2022) -
Mycobacterium marinum: a potential immunotherapy for Mycobacterium tuberculosis infection
by: Tian WW, et al.
Published: (2013)